Table 5.
Results of sensitivity analysis based on blinded studies using Random effect model.
| Statistics (95% CI) | Name of marker | ROMA | |||
|---|---|---|---|---|---|
| HE4 | CA 125 | ROMA All | ROMA Pre-menopause |
ROMA Post-menopause |
|
| Sensitivity | 0.73 (0.71–0.75) | 0.85 (0.83–0.87) | 0.85 (0.83–0.87) | 0.82 (0.79–0.85) | 0.87 (0.85–0.89) |
| Specificity | 0.89 (0.88–0.90) | 0.70 (0.69–0.72) | 0.75 (0.73–0.76) | 0.75 (0.73–0.77) | 0.81 (0.80–0.83) |
| LR + ve | 9.37 (5.90–14.88) | 2.61 (2.17–3.13) | 4.39 (2.94–6.56) | 4.19 (2.91–6.01) | 5.56 (3.81–8.11) |
| LR –ve | 0.26 (0.19–0.36) | 0.22 (0.16–0.30) | 0.18 (0.12–0.26) | 0.23 (0.16–0.32) | 0.16 (0.11–0.22) |
| Diagnostic odds ratio | 37.88 (23.89–60.05) | 12.38 (8.48–18.08) | 25.70 (14.91–44.27) | 19.44 (11.42–33.11) | 38.21 (24.05–60.70) |
| Tau-square (%) | 76.1 | 78.3 | 94.15 | 73.4 | 52.5 |
| Cochrane-Q | 66.94 (P = 0.001) | 82.84 (P = 0.001) | 105.26 (P = 0.001) | 56.39 (P = 0.001) | 40.46 (P = 0.001) |
| Spearman’s correlation | 0.57 (P = 0.017) | − 0.07 (P = 0.778) | 0.07 (P = 0.791) | 0.07 (P = 0.791 | 0.35 (P = 0.171) |
| Symmetrical ROC (SROC) | |||||
|
AUC (SE) Q* index |
0.90 (0.01) 0.83 (0.02) |
0.83 (0.03) 0..76 (0.03) |
.91 (0.019) 0..84 (0.021) |
0.89 (0.02) 0.82 (0.02) |
0.93 (0.012) 0.86 (0.015) |
Human epididymis secretory protein 4 (HE4), Cancer antigen (CA125) and Risk of Ovarian Malignancy Algorithm (ROMA). Positive Likelihood ratio (LR + ve), Negative Likelihood ratio (LR–ve), Standard error (SE), Receiver operating characteristic curve (ROC), Area under curve (AUC).